Chugai Pharmaceutical Co., Ltd. (4519)

Basic

  • Market Cap

    ¥8,611.36B

  • EV

    ¥7,992.6B

  • Shares Out

    1,645.27M

  • Revenue

    ¥1,276.05B

  • Employees

    7,771

Margins

  • Gross

    58.14%

  • EBITDA

    37.35%

  • Operating

    36.6%

  • Pre-Tax

    36.86%

  • Net

    26.39%

  • FCF

    15.09%

Returns (5Yr Avg)

  • ROA

    15.41%

  • ROE

    22.47%

  • ROCE

    30.42%

  • ROIC

    30.43%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    ¥4,981.43

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    ¥775.65

  • Earnings (Dil)

    ¥204.65

  • FCF

    ¥117.05

  • Book Value

    ¥932.97

Growth (CAGR)

  • Rev 3Yr

    19.18%

  • Rev 5Yr

    17.37%

  • Rev 10Yr

    11.69%

  • Dil EPS 3Yr

    18.44%

  • Dil EPS 5Yr

    31.4%

  • Dil EPS 10Yr

    19.46%

  • Rev Fwd 2Yr

    -7.03%

  • EBITDA Fwd 2Yr

    -8.85%

  • EPS Fwd 2Yr

    -6.13%

  • EPS LT Growth Est

    0.37%

Dividends

  • Yield

    —

  • Payout

    19.54%

  • DPS

    ¥40

  • DPS Growth 3Yr

    -0.82%

  • DPS Growth 5Yr

    13.4%

  • DPS Growth 10Yr

    11.07%

  • DPS Growth Fwd 2Yr

    4.29%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Revenues

527,844.0

588,896.0

633,314.0

802,836.0

1,039,247.0

1,136,650.0

Other Revenues, Total

51,943.0

97,288.0

153,632.0

196,923.0

220,699.0

139,401.0

Total Revenues

579,787.0

686,184.0

786,946.0

999,759.0

1,259,946.0

1,276,051.0

Total Revenues % Chg.

8.5%

18.4%

14.7%

27.0%

26.0%

11.6%

Cost of Goods Sold, Total

262,847.0

266,071.0

273,465.0

338,147.0

476,251.0

534,154.0

Gross Profit

316,940.0

420,113.0

513,481.0

661,612.0

783,695.0

741,897.0

Selling General & Admin Expenses, Total

93,416.0

101,574.0

94,401.0

102,416.0

100,760.0

112,702.0

R&D Expenses

99,202.0

107,942.0

117,850.0

137,299.0

149,626.0

178,244.0

Other Operating Expenses

—

—

—

—

—

-16,122.0

Other Operating Expenses, Total

192,618.0

209,516.0

212,251.0

239,715.0

250,386.0

274,824.0

Operating Income

124,322.0

210,597.0

301,230.0

421,897.0

533,309.0

467,073.0

Interest Expense, Total

-111.0

-125.0

-62.0

-48.0

-61.0

-35.0

Interest And Investment Income

449.0

545.0

—

—

52.0

3,042.0

Net Interest Expenses

338.0

420.0

-62.0

-48.0

-9.0

3,007.0

Currency Exchange Gains (Loss)

—

—

—

—

—

—

Other Non Operating Income (Expenses)

-3,211.0

-3,124.0

-2,980.0

-2,464.0

-2,134.0

267.0

EBT, Excl. Unusual Items

121,449.0

207,893.0

298,188.0

419,385.0

531,166.0

470,347.0

Gain (Loss) On Sale Of Investments

—

—

—

—

—

—

Asset Writedown

—

—

—

—

—

—

EBT, Incl. Unusual Items

121,449.0

207,893.0

298,188.0

419,385.0

531,166.0

470,347.0

Income Tax Expense

28,370.0

50,333.0

83,455.0

116,390.0

156,737.0

133,602.0

Earnings From Continuing Operations

93,079.0

157,560.0

214,733.0

302,995.0

374,429.0

336,745.0

Minority Interest

-591.0

—

—

—

—

—

Net Income

92,488.0

157,560.0

214,733.0

302,995.0

374,429.0

336,745.0

Net Income to Common Incl Extra Items

92,488.0

157,560.0

214,733.0

302,995.0

374,429.0

336,745.0

Net Income to Common Excl. Extra Items

92,488.0

157,560.0

214,733.0

302,995.0

374,429.0

336,745.0

Total Shares Outstanding

1,641.7

1,642.6

1,643.9

1,644.3

1,645.0

1,645.3

Weighted Avg. Shares Outstanding

1,641.1

1,642.1

1,643.4

1,644.2

1,644.8

1,645.1

Weighted Avg. Shares Outstanding Dil

1,643.7

1,644.5

1,645.1

1,645.2

1,645.3

1,645.4

EPS

56.4

95.9

130.7

184.3

227.6

204.7

EPS Diluted

56.3

95.8

130.5

184.2

227.6

204.6

EBITDA

140,900.0

236,998.0

331,606.0

452,765.0

564,743.0

476,556.0